Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novel leukaemia markers

K J Micklem1

  • 1Department of Cellular Science, John Radcliffe Hospital, Oxford, UK.

Bioscience Reports
|December 1, 1995
PubMed
Summary
This summary is machine-generated.

Researchers developed novel antibodies targeting specific leukemia markers and all T or B lymphocytes for improved cancer diagnosis. These reagents show promise in diagnosing various hematologic disorders and have applications beyond leukemia.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Markers of de novo lipogenesis in adipose tissue: associations with small adipocytes and insulin sensitivity in humans.

Diabetologia·2009
Same author

Identification of the CD85 antigen as ILT2, an inhibitory MHC class I receptor of the immunoglobulin superfamily.

Journal of leukocyte biology·1999
Same author

A novel internal antigen which distinguishes germinal centre cells from other B-cell types.

Immunology·1994
Same author

A new macrophage differentiation antigen which is a member of the scavenger receptor superfamily.

European journal of immunology·1993
Same author

HML-1 antigen on mucosa-associated T cells, activated cells, and hairy leukemic cells is a new integrin containing the beta 7 subunit.

The American journal of pathology·1991
Same author

Different isoforms of human FcRII distinguished by CDw32 antibodies.

Journal of immunology (Baltimore, Md. : 1950)·1990
Same journal

Bacterial heteroresistance mechanisms, dynamics, and emerging diagnostic approaches.

Bioscience reports·2026
Same journal

Expression of Concern: Exosomes derived from circRNA Rtn4-modified BMSCs attenuate TNF-α-induced cytotoxicity and apoptosis in murine MC3T3-E1 cells by sponging miR-146a.

Bioscience reports·2026
Same journal

Evaluation of correlations between serum and urinary vitamin D metabolites using LC-MS/MS.

Bioscience reports·2026
Same journal

The evolving therapeutic landscape of gut-pancreatic peptide signalling in metabolic disorders: from mono- to multi-agonist therapies.

Bioscience reports·2026
Same journal

A peripheral blood-based approach involving vimentin along with AURKA enabled efficient tracking of elusive Oct4/Sox2-expressing disseminated breast cancer stem cells.

Bioscience reports·2026
Same journal

MCM2-7 proteins promote NF-κB transcriptional activity through cooperative promoter recruitment.

Bioscience reports·2026
See all related articles

Area of Science:

  • Immunology
  • Oncology
  • Hematology

Background:

  • Leukemia diagnosis relies on identifying specific cellular markers.
  • Current diagnostic tools may lack specificity for certain lymphocyte populations or neoplastic transformations.

Purpose of the Study:

  • To develop novel monoclonal antibodies and polyclonal antisera for enhanced leukemia diagnosis.
  • To create reagents that can identify all T or B lymphocytes in fixed tissue sections.
  • To generate antibodies against key molecules implicated in neoplastic transformations, such as bcl-2, tal-1, and HRX.

Main Methods:

  • Immunization with synthetic peptides or recombinant proteins to generate antibodies.
  • Production of monoclonal antibodies and polyclonal antisera.
  • Testing antibody specificity for T and B lymphocytes in paraffin-embedded sections.

Related Experiment Videos

  • Characterization of antibodies against specific oncogenic proteins (bcl-2, tal-1, HRX).

    • Main Results:

    • Successfully produced reagents that recognize all T or all B lymphocytes in fixed paraffin sections.
    • Developed monoclonal antibodies targeting bcl-2 (follicular lymphoma), tal-1 (T-cell acute leukemias), and HRX (hematologic disorders).
    • Demonstrated the utility of these reagents in diagnostic applications for leukemia and other hematologic conditions.

    Conclusions:

    • Novel antibodies offer unique capabilities for identifying lymphocyte populations and specific oncogenic proteins.
    • These reagents have proven useful in leukemia diagnosis and show significant potential in broader hematologic disorder diagnostics.
    • The developed antibodies represent valuable tools for both diagnostic and research applications in hematologic malignancies.